Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28082087 | 0.98 | HTT (0.50) | HTTFGFR1TDP1POLBTNF | |
| SCHEMBL10889581 | 0.83 | TDP1 (0.52) | HTTFGFR1TDP1POLBTNF | |
| SCHEMBL7804822 | 0.83 | TDP1 (0.52) | HTTFGFR1TDP1POLBTNF | |
| SCHEMBL29182106 | 0.81 | TDP1 (0.43) | HTTFGFR1TDP1POLBTNF | |
| SCHEMBL6006528 | 0.79 | TDP1 (0.48) | HTTFGFR1TDP1POLBTNF | |
| SCHEMBL30371909 | 0.79 | TDP1 (0.53) | HTTTDP1POLBTNFCYP11B1 | |
| SCHEMBL718648 | 0.79 | TDP1 (0.53) | HTTTDP1POLBTNFCYP11B1 | |
| SCHEMBL1344383 | 0.79 | TDP1 (0.48) | HTTFGFR1TDP1POLBTNF | |
| Bromide SCHEMBL38655438 | 0.78 | TDP1 (0.52) | HTTTDP1POLBTNFCYP11B1 | |
| SCHEMBL2386044 | 0.75 | FGFR1 (0.33) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433203-A | Amine fluorinated curcumenol derivative compound and application and preparation method thereof | 华东理工大学 | 2022-12-06 | — | — | CN | claimed |
| CN-108383835-A | Pyrido [1,2-a] the benzimidazole hypochlorous acid fluorescence probe of indoles modification and its application | 泰山医学院 | 2018-08-10 | — | — | CN | claimed |
| CN-108285448-A | Pyrido [1,2-a] the benzimidazole SO of benzimidazole modification32-Ratio fluorescent probe and its application | 泰山医学院 | 2018-07-17 | — | — | CN | claimed |
| CN-108218866-A | Pyrido benzimidazole mercury ion ratio fluorescent probe and its application | 泰山医学院 | 2018-06-29 | — | — | CN | claimed |
| CN-102227409-B | Pyridine-3-carboxyamide derivative | KOWA CO | 2014-03-26 | — | — | CN | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | claimed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | claimed |
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | claimed |
| US-7358248-B2 | Substituted amino carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | claimed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | claimed |
| EP-0601486-B1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD (KR) | 1997-10-29 | — | — | EP | claimed |
| CN-1150799-A | Benzoheterocyclic derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-05-28 | — | — | CN | claimed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | claimed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | claimed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | claimed |
| US-4808620-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIALLERGENS, ANTIARTHRITIC, ANTIRHEUMATIC AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | HTT 952/4885FGFR1 2284/4885TDP1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.